Skip to main content

Posts tagged with "The Dark Side"

  • Cardiovascular Disease

    Vytorin: It’s A Pity

    Ezetimibe, known as Zetia and as the key component of Vytorin, was invented by friends and colleagues of mine. It was the first drug I ever saw discovered after I joined the drug industry. The initial discovery of the whole compound class happened around the corner from my lab, and the compound that became ezetimibe… Read More
  • The Dark Side

    Fakery And Its Ends

    Thinking about that plagiarizing Indian professor brings up the same thought I always have in these situations: what on Earth is going through the heads of these people? I can tell you, honestly, that I have never faked any data. (That phrase makes me remember, though, that one of the most crazed fabulists I’ve ever… Read More
  • The Dark Side

    Big Steaming Heaps of Fraud

    Since I had a blog entry here recently talking about plagiarism, I thought I should point out a whopping case of it that’s come to light. One Pattium Chiranjeevi, a professor of chemistry at Sri Venkateswara University in Triupati, India, has been accused of cranking out dozens of forged publications over the last few years. Read More
  • Diabetes and Obesity

    More On Merck and Taranabant

    My piece on Merck last week seems to have touched a few nerves, if some of the comments and e-mails I’ve received are any sign. To clarify things: I agree that Merck is still doing some excellent science, as they always have. And they still have a lot of good people there, as they always… Read More
  • Diabetes and Obesity

    What You Become Known For

    A recent item from InVivoBlog about Merck which brought up some interesting points. They aren’t cheerful ones. The article is largely about Merck’s reputation, which has taken some dents in recent years, to put it lightly. The Vioxx debacle is the main reason for this, but the hits have kept on coming, such as the… Read More
  • The Dark Side

    Recycle, Reuse, Republish

    There’s an analysis in the latest Nature that puts some numbers on a problem that scientists the world over have suspected for some time: the number of duplicate papers that show up in the literature. The authors used this online text-similarity tool to go through papers in Pubmed, and found a small (but not as… Read More
  • Biological News

    Visfatin: Real Or Not?

    A commentor to my Proteomics 101 post the other day brought up an important point: that before you can have a chance to figure out what a protein is doing, you have to know that it exists. Finding the darn things is no small job, since you’re digging through piles of chemically similar stuff to… Read More
  • Clinical Trials

    Pecunia Non Olet?

    Today’s New York Times had a long front-page story from Janet Roberts and the paper’s Scourge of the Drug Industry, Gardiner Harris. Titled “After Sanctions, Doctors Get Drug Company Pay”, it details (through the example of one particular Minnesota psychiatrist) a practice of physicians who have had medical board problems co… Read More
  • Clinical Trials

    FDA Advisory Panels: Pay, No Play

    Jim Hu has a good post on some proposed new FDA rules for its advisory panel members. Some sort of changes have been coming for a while now – here’s an op-ed that I wrote on the subject back in 2005. I argued that many of the best scientists and clinicians in a given field… Read More
  • Business and Markets

    The Great Plavix Disaster

    I’ve been remiss in not covering the Plavix situation, which is quite a story. The huge-selling anticoagulant is marketed in the US by Bristol-Meyers Squibb and in the rest of the world by Sanofi-Aventis. It’s been the target of the Canadian generic firm Apotex, who’ve maintained that key parts of its patent coverage are invalid. Read More